Santhera Pharmaceuticals (Schweiz) AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Santhera Pharmaceuticals (Schweiz) AG - overview
Established
2004
Location
-, -, Switzerland
Primary Industry
Pharmaceuticals
About
Based in Switzerland, Santhera Pharmaceuticals focuses on developing innovative medicines for rare neuromuscular diseases, with a commitment to enhancing patient health outcomes. Santhera Pharmaceuticals specializes in creating treatments for rare neuromuscular diseases. Founded in 2004 in Liestal, Switzerland, the company has successfully completed 19 deals to date. Notably, on November 3, 2006, Santhera raised CHF 88.
50 million through a PIPE funding round led by Highbridge Capital Management, contributing to a total amount raised of CHF 2. 20 million. The company was formed by a group of individuals committed to addressing unmet medical needs in this niche market. Santhera Pharmaceuticals specializes in the development and commercialization of innovative medicines aimed at addressing the needs of patients suffering from rare neuromuscular diseases.
The company’s core products include AGAMREE® (vamorolone), which targets Duchenne muscular dystrophy (DMD), a condition that severely impacts the mobility and quality of life of affected individuals. Santhera’s products are designed to provide treatment options where none previously existed, thereby improving health outcomes for patients. The company primarily serves healthcare professionals, patients, and caregivers across various geographical markets, including Europe and North America. By focusing on high unmet medical needs, Santhera aims to enhance the lives of children and adults living with these debilitating conditions.
In 2022, Santhera Pharmaceuticals generated revenue of CHF 7,832,914. 90. The company operates on a business-to-business (B2B) model, partnering with wholesalers and healthcare institutions to distribute its medications, particularly AGAMREE® (vamorolone). While specific pricing plans for individual products are not disclosed, the revenue structure is based on direct sales and supply agreements designed to ensure access to these critical therapies.
Santhera Pharmaceuticals plans to expand its product portfolio with new medications targeting rare neuromuscular diseases, with potential launches expected within the next few years. The company is also looking to enter new markets in Europe and North America by the end of 2024. The recent funding from the PIPE round will support these initiatives, providing necessary financial resources to enhance research and development efforts.
Current Investors
Highbridge Capital Management, Yorkville Advisors, IRIS Capital Investment
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.santhera.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Santhera Pharmaceuticals (Schweiz) AG - timeline of key events
Santhera Pharmaceuticals (Schweiz) AG - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 4,321,000 | 19,033,000 | 22,943,000 | 31,657,000 | 75,376,000 | 15,008,000 | (1,595,000) | - | - | - |
| % Revenue Growth (YoY) | - | 340.5% | 20.5% | 38.0% | 138.1% | (80.1%) | (110.6%) | - | - | - |
| EBITDA (USD) | 4,295,000 | (29,863,000) | (47,072,000) | (47,679,000) | (5,671,000) | (45,939,000) | (53,164,000) | - | - | - |
| Operating Income (USD) | 3,173,000 | (33,127,000) | (50,454,000) | (51,420,000) | (10,442,000) | (53,076,000) | (56,888,000) | - | - | - |
| Operating Margin | 73.4% | (174.1%) | (219.9%) | (162.4%) | (13.9%) | (353.7%) | 3566.6% | - | - | - |
| % EBITDA Margin | 99.4% | (156.9%) | (205.2%) | (150.6%) | (7.5%) | (306.1%) | 3333.2% | - | - | - |
| NET Income (USD) | 5,949,000 | (35,415,000) | (51,532,000) | (54,186,000) | (18,973,000) | (67,659,000) | (55,526,000) | - | - | - |
| % Net Margin | 137.7% | (186.1%) | (224.6%) | (171.2%) | (25.2%) | (450.8%) | 3481.3% | - | - | - |
Santhera Pharmaceuticals (Schweiz) AG - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.